文献速递消化内镜

一项III期研究评估瑞马唑仑(CNS 7056)与安慰剂及咪达唑仑在结肠镜检查患者中的疗效与安全性

A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy.
PubMed 文献 · Gastrointest Endosc · 2018-04-30

这项随机双盲III期研究在美国12个中心纳入461例门诊结肠镜检查患者,比较瑞马唑仑与安慰剂及开放标签咪达唑仑。瑞马唑仑组达到主要复合终点的比例为91.3%,显著高于安慰剂组的1.7%(P<.0001)。瑞马唑仑可安全地在内镜医师监督下给药,且神经精神功能恢复快于安慰剂(咪达唑仑补救)和咪达唑仑组。

要点

  • 瑞马唑仑组主要复合终点达标率91.3%,安慰剂组1.7%(P<.0001)。
  • 瑞马唑仑组芬太尼用量更少,神经精神功能恢复更快,更早达到离院标准。
  • 瑞马唑仑组低血压发生率更低,瑞马唑仑或咪达唑仑组缺氧发生率均为1%。

核心结论

  • 瑞马唑仑可在内镜医师监督下安全用于门诊结肠镜检查,且与安慰剂(咪达唑仑补救)和咪达唑仑相比神经精神功能恢复更快。

研究设计与样本

  • 随机双盲比较瑞马唑仑与安慰剂用于门诊结肠镜检查,另设开放标签咪达唑仑组,随机比例为瑞马唑仑:安慰剂:咪达唑仑=30:6:10。
  • 研究药物在内镜医师监督下给药,无麻醉专科医师参与。
  • 患者在研究药物给药前给予芬太尼50至75 μg。
  • 任何组别未达到充分镇静者按研究者判断使用咪达唑仑补救。
  • 主要终点为复合终点,需满足3项标准:完成结肠镜检查、无需补救药物、任何15分钟间隔内瑞马唑仑或安慰剂给药≤5次(开放标签咪达唑仑组为任何12分钟间隔内≤3次)。

主要发现

  • 瑞马唑仑组、安慰剂组和咪达唑仑组达到主要终点的患者比例分别为91.3%、1.7%和25.2%(瑞马唑仑 vs 安慰剂 P<.0001)。
  • 瑞马唑仑组患者芬太尼用量少于安慰剂组和咪达唑仑组。
  • 瑞马唑仑组神经精神功能恢复快于安慰剂组和咪达唑仑组,更早达到离院标准,更快感觉恢复正常。
  • 瑞马唑仑组低血压发生率低于安慰剂组和咪达唑仑组。
  • 瑞马唑仑组或咪达唑仑组缺氧发生率均为1%。

关键数值与推荐

  • 主要终点达标率:瑞马唑仑组91.3% vs 安慰剂组1.7%(P<.0001)。
  • 主要终点达标率:瑞马唑仑组91.3% vs 咪达唑仑组25.2%。
  • 缺氧发生率:瑞马唑仑组1%,咪达唑仑组1%。

临床怎么用

  • 瑞马唑仑可在内镜医师监督下用于门诊结肠镜检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Remimazolam is an ultrashort-acting benzodiazepine. METHODS: We performed a randomized double-blind comparison of remimazolam to placebo for outpatient colonoscopy. This study design was a requirement of the U.S. Food and Drug Administration. An additional group was randomized to open-label midazolam administered according to its package insert instructions (the randomization ratio for remimazolam:placebo:midazolam was 30:6:10). Study medications were administered under the supervision of the endoscopist, without any involvement of an anesthesia specialist. Patients were given 50 to 75 μg of fentanyl before receiving study medications. Patients who failed to achieve adequate sedation in any arm were rescued with midazolam dosed at the investigator's discretion. The primary endpoint was a composite that required 3 criteria be met: completion of the colonoscopy, no need for rescue medication, and ≤5 doses of remimazolam or placebo in any 15-minute interval (≤3 doses of midazolam in any 12-minute interval in the open-label midazolam arm). RESULTS: There were 461 randomized patients in 12 U.S. sites. The primary endpoint was met for remimazolam, placebo, and midazolam in 91.3%, 1.7%, and 25.2% of patients, respectively (P < .0001 for remimazolam vs placebo). Patients administered remimazolam received less fentanyl, had faster recovery of neuropsychiatric function, were ready for discharge earlier, and felt back to normal sooner than patients with both placebo and midazolam. Hypotension was less frequent with remimazolam, and hypoxia occurred in 1% of patients with remimazolam or midazolam. There were no treatment-emergent serious adverse events. CONCLUSION: Remimazolam can be administered safely under the supervision of endoscopists for outpatient colonoscopy, and it allows faster recovery of neuropsychiatric function compared with placebo (midazolam rescue) and midazolam. (Clinical trial registration number: NCT02290873.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Rex DK, Bhandari R, Desta T, et al. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018. PMID: 29723512. doi:10.1016/j.gie.2018.04.2351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。